AstraZeneca's global oncology business Dato-DXd and Lung Cancer Business Unit Head Ming-Long Lai has decided to resign.

The journalist learned that Lai Minglong, head of AstraZeneca's global oncology business unit Dato-DXd and lung cancer division, has decided to resign and seek external development opportunities, with his last working day being June 30. AstraZeneca confirmed the news to the reporter. Public information shows that Lai Minglong joined AstraZeneca in June 2017 as the Vice President of the Cardiovascular and Metabolic Business Unit in China, and was promoted to General Manager of AstraZeneca China in 2018.